BioSpace News Archive

Drug Development

bluebird’s SCD Gene Therapy Released from Partial Hold

The FDA lifted its partial clinical hold on bluebird’s experimental sickle cell disease gene therapy for patients younger than 18.

December 20, 2022
·
2 min read
·
Tristan Manalac
Business

Voyager’s Al Sandrock, Alnylam’s Yvonne Greenstreet and More Share Their Predictions for 2023

BioSpace spoke with several leaders to gather their thoughts and predictions for the new year. Here is the first installment of this two-part series.

December 20, 2022
·
6 min read
·
Heather McKenzie
Drug Development

FDA Places Clinical Hold on Entrada’s IND for Duchenne Muscular Dystrophy

The FDA placed a clinical hold on Entrada’s experimental DMD candidate.

December 20, 2022
·
2 min read
·
Alex Keown
Business

Novartis’ Restructuring Claims 285 Jobs in New Jersey

Novartis will eliminate 285 jobs across units in New Jersey. The terminations will take effect on January 28, 2023.

December 20, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Verona Pharma Eyes NDA for COPD Drug Based on Positive Phase III Data

Verona Pharma’s COPD candidate hits the mark in late-stage testing.

December 20, 2022
·
2 min read
·
Alex Keown
Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers

Nykode Therapeutics ASA announced an expanded clinical development plan for VB10.16, the Company’s wholly-owned cancer vaccine, for the treatment of HPV16-positive cancers with high unmet need.

December 20, 2022
·
6 min read
Drug Development

REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH Annual Meeting

REGiMMUNE Limited announced the positive results of their Phase 2b clinical trial for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation at the 2022 American Society of Hematology Annual Meeting.

December 20, 2022
·
4 min read
Policy

Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension

Idorsia Ltd announced that it has submitted a New Drug Application to the US Food and Drug Administration seeking approval for aprocitentan, Idorsia’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult-to-control hypertension.

December 20, 2022
·
13 min read
Business

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements-December 20, 2022

RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. a clinical-stage central nervous system biopharmaceutical company, today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals’ wholly owned subsidiary, NeuroRx, Inc.

December 20, 2022
·
4 min read
Drug Development

AlzeCure gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer’s

AlzeCure Pharma announced that an abstract with new preclinical data supporting a disease-modifying effect of ACD856 has been accepted for presentation at the Alzheimer’s Conference AD/PD 2023, to be held in Gothenburg, Sweden, March 28 - April 1.

December 20, 2022
·
6 min read